-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Surpassing Pfizer, Hengrui has become the fourth pharmaceutical company
with the highest number of clinical trials in the world.
In the past calendar year, more than 10,000 Phase I-III clinical trials have been initiated worldwide, and China has surpassed the United States as the leading force
in clinical trials with a growth rate of 37%.
In 2020, global clinical trials were affected by the new crown epidemic, and 2021 rebounded strongly, with the number of clinical trials increasing by 6%
year-on-year.
New crown, oncology, chronic diseases, and rare diseases are the key areas
of global pharmaceutical companies.
In 2021, the number of phase I-III trials ranked among the top 10 industry sponsors/partners
Pharma
According to Intelligence's 2021 Clinical Trials Review, more studies were initiated in China in 2021 than in any other country, while the clinical trial activities of large pharmaceutical companies focused on solid tumors and showed a trend
of increasing R&D focus.
01 Hengrui surpassed Pfizer and approached the top three
Hengrui surpassed Pfizer and approached the top threeHengrui, which ranked 10th in 2019 with 69 clinical trials, surpassed Pfizer in just two years with 130 clinical trials and reached the fourth place among the top ten sponsors in the world
.
In terms of overall ranking, the ranking of the top ten trial sponsors in 2021 is almost the same as the previous year, and in terms of quantity, the number of companies entering the clinic has increased
.
AZ added 15 clinical trials a year after peaking in 2020 with 157 clinical trials, and this year it has been the most active sponsor with 172 clinical trials
.
There have also been some changes at the end of the list, with GSK replacing Sanofi to return to No.
10
.
BMS, which ranked first among clinical trial sponsors in 2019, has slipped to 8th this year
.
Pharma
Intelligence believes that the reason may be due
to the merger of BMS's products with Celgene's products.
And from the perspective of clinical trial types, the number of phase III clinical trials of BMS is not dominant, but the number of early studies accounts for a relatively large
proportion.
At Pharma
According to Intelligence, Hengrui's rapid growth also reflects the increased
influence of Chinese pharmaceutical companies on the global stage.
In recent years, Hengrui has continued to increase investment
in research and development.
According to the third quarterly report of 2022, Hengrui's R&D expenditure reached 3.
498 billion yuan, and it is estimated that Hengrui's R&D investment is expected to exceed 4.
5 billion yuan
this year.
According to Hengrui's previous disclosure, the company has listed 11 innovative drugs, more than 60 innovative drugs are under clinical development, and more than 260 clinical trials have been carried out
at home and abroad.
Pharma
Intelligence boldly predicts that it is not impossible
for Hengrui or a company of the same type to leap to the top of this list in the future.
From the perspective of clinical trial classification, Novartis has the largest proportion of phase III clinical trials among the top ten companies, and the absolute number is the largest
.
Roche had the highest number of Phase III clinical trials in 2020, and its portfolio in 2021 was primarily focused on early-stage clinical trials
.
Hengrui and Pfizer also account for a relatively large number of early-stage trials, and more than half of the trials are phase I or phase I/II
.
The main types of diseases in clinical trials carried out by the top ten sponsors also have their own characteristics
.
The types of diseases that the top ten sponsors focus on are becoming more and more concentrated
.
Pharma
Intelligence shows that among the top three key indications of each company, there are 17 different indications in 2021, 19 in 2020, and 22 in 2019, and the continuous reduction of types also indicates that the research overlap of the head companies is higher
.
In the first three major clinical trial types of AZ, Pfizer and Johnson & Johnson, there has been research and development
related to the new coronavirus.
Among them, the number of Pfizer's new crown-related clinical trials reached 24
.
The blessing of the two new crown products has allowed Pfizer to return to the throne
of the top 50 global pharmaceutical companies in 2021.
According to the 2022Q3 financial report, in the third quarter of this year alone, the revenue of the new crown vaccine Comirnaty reached $4.
402 billion, and Comirnaty's revenue in the first three quarters reached $26.
477 billion, up 9%
year-on-year.
The sales of the new crown oral drug Paxlovid reached 7.
514 billion US dollars in the third quarter, and the total revenue in the first three quarters was 17.
199 billion US dollars
.
In other words, the two new crown products have generated nearly $44 billion in revenue for Pfizer in the first three quarters of this year alone, and it is understandable that Pfizer has invested a lot of research and development for this
.
related to the new coronavirus.
Non-small cell lung cancer is still the primary focus of pharmaceutical companies, including AZ, Merck, Novartis, and BMS
.
Among them, AZ has carried out a total of 30 clinical trials in the field of non-small cell lung cancer, and Merck, Novartis and BMS have 16, 10 and 13 clinical trials
with non-small indications, respectively.
In addition to focusing on the new crown and oncology fields, many companies have focused on type II diabetes (T2D), kidney disease, Crohn's disease, dyslipidemia, multiple sclerosis, obesity, pain
, etc.
For example, Eli Lilly and Hengrui both take type II diabetes as the top three research priorities
.
02 The number of clinical trials in China is overwhelming
The number of clinical trials in China is overwhelmingThe report also shows how
pilot activities have been carried out in different regions.
Pharma
Intelligence said the U.
S.
and China have been competing for the top two in the number of trials conducted across all therapeutic areas over the past few years
.
According to Clarivate Care's 2020 data, the number of clinical trials conducted in China has exceeded that of the United States for the first time in the
first half of 2020.
S.
and China have been competing for the top two in the number of trials conducted across all therapeutic areas over the past few years
.
China became the country with the largest number of trials in 2021, initiating 3,795 new clinical trials compared to 3,310 in the United States
.
In terms of growth rate, the growth rate of new clinical trials in the United States is 6%, while the growth rate of new clinical trials in China is as high as 37%.
Pharma
Intelligence expects this momentum to see the gap between the two countries widen
in the future.
After China and the United States, European countries such as France, Germany, Italy, Spain, and the United Kingdom, together with Canada, Japan, and Australia, ranked other among the ten countries with the most clinical trials after 2021
.
At Pharma
Among the distribution of trials in various therapeutic areas announced by Intelligence, China occupies the top position in autoimmune/inflammation, oncology, cardiovascular, metabolic/endocrinology, and genitourinary systems, while the United States has the largest number of
trials in the fields of central nervous system, infectious diseases, and ophthalmology.
According to the "Annual Report on Clinical Trial Progress of New Drug Registration in China (2021)" released by CDE in June this year, the total number of annual registrations on the drug clinical trial registration and information disclosure platform exceeded 3,000 for the first time in 2021, an overall increase of nearly 30% over 2020, and the proportion of new drug clinical trials has also shown a year-by-year growth trend in the past three years, exceeding 60%
in 2021.
From the perspective of specific drug types, chemical drugs will still be the main clinical trials in China in 2021, accounting for 70.
8%; Biological products followed with 26.
7%, with Chinese medicine being the least, at 2.
4%.
Compared with the data of the past three years, the proportion of clinical trials of various drugs is similar, but the proportion of biological products is increasing year by year, and the proportion of chemical drugs and traditional Chinese medicines is decreasing year by year
.
In the clinical trials of new drugs, 1069 (52.
6%), 886 (43.
6%) and 78 (3.
8%)
of chemical drugs, biological products and traditional Chinese medicines were registered, respectively.
From the trend of the proportion of various drugs, the number of biological product trials increased significantly, with the number of registrations in 2020 and 2021 increasing by 31.
5% and 46.
4% respectively over the previous year, and the number of registrations in 2019 and 2020 was 460 and 605 respectively
.
The number of clinical trials has increased significantly, and the research and development of domestic innovative targets is becoming increasingly hot
.
According to the growth trend of the number of clinical trials in China in recent years and the estimation of project prices, the clinical trial market size will exceed 60 billion in 2022 and will grow rapidly
at an annual rate of 10 billion.
